| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/07/2002 | WO2002009705A2 Agonist of follicle stimulating hormone activity |
| 02/07/2002 | WO2002009701A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
| 02/07/2002 | WO2002009700A1 Cancer treatment by combination therapy |
| 02/07/2002 | WO2002009696A1 Methods for treating cell proliferative disorders and viral infections |
| 02/07/2002 | WO2002009690A2 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent |
| 02/07/2002 | WO2002009686A2 Cdc25 phosphatase inhibitors |
| 02/07/2002 | WO2002009680A2 Pharmacologically active substance for treating cardiovascular disorders |
| 02/07/2002 | WO2002009679A2 Use of 13-cis retinoic acid for the treatment of emphysema |
| 02/07/2002 | WO2002009667A2 Dispersions for formulating slightly or poorly soluble active ingredients |
| 02/07/2002 | WO2002009645A2 Intercellular transport protein linked to an antigen as a molecular vaccine |
| 02/07/2002 | WO2002009631A1 Vaginal delivery of bisphosphonates |
| 02/07/2002 | WO2001081310A8 1-aroyl-piperidinyl benzamidines |
| 02/07/2002 | WO2001078652A3 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 02/07/2002 | WO2001075066A3 Dna molecules and polypeptides of pseudomonas syringae hrp pathogenicity island and their uses |
| 02/07/2002 | WO2001062911A3 Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses |
| 02/07/2002 | WO2001060417A3 Radioactive therapeutic liposomes |
| 02/07/2002 | WO2001059127A3 Drug metabolizing enzymes |
| 02/07/2002 | WO2001056589A3 Physiologically active compositions of basidiomycotina and araliaceae extracts |
| 02/07/2002 | WO2001053469A3 Phosphatases |
| 02/07/2002 | WO2001044294A3 Compositions and methods for inhibiting endothelial cell proliferation |
| 02/07/2002 | WO2001041747A3 Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer |
| 02/07/2002 | WO2001040240A3 Mono- and disaccharide derivatives |
| 02/07/2002 | WO2001035935B1 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 02/07/2002 | WO2001034206A3 Nucleic acid-containing complex |
| 02/07/2002 | WO2001030333A3 Tissue factor antagonists and methods of use thereof |
| 02/07/2002 | WO2001029233A3 Chimeric immunogenic compositions and nucleic acids encoding them |
| 02/07/2002 | WO2001010382A3 Compositions and methods related to claudin-7 |
| 02/07/2002 | WO2000032578A8 Benzimidazole compounds that are vitronectin receptor antagonists |
| 02/07/2002 | US20020016976 Mutant multi-substrate enzyme which accepts at least one orthogonal substrate analog, whereby catalytic activity results in combination of all or part of orthogonal substrate with other substrate of enzyme; drug screening |
| 02/07/2002 | US20020016471 Inhibitors of p38 |
| 02/07/2002 | US20020016370 A therapeutically effective amount of exo-R-mecamylamine or salt, substantially free of exo-S-mecamylamine in combination with a carrier; useful for treating substance addiction |
| 02/07/2002 | US20020016362 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 02/07/2002 | US20020016361 Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
| 02/07/2002 | US20020016360 Method of diminishing the adverse effects of interleukin-2 |
| 02/07/2002 | US20020016356 Antitumor agents |
| 02/07/2002 | US20020016355 Synthetic pathway relies upon stereospecific synthesis of oxazoline intermediate and stereoselective addition of formyl amide to oxazoline |
| 02/07/2002 | US20020016354 Treatment of respiratory diseases, convulsions, vascular disorders, renal disorders, urinary disorders, Alzheimer's disease, dysmenorrhea, narcolepsy |
| 02/07/2002 | US20020016353 Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions |
| 02/07/2002 | US20020016352 Cancer treatment with Go6976 and its related compounds |
| 02/07/2002 | US20020016342 Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 02/07/2002 | US20020016336 Treatment of rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration, tumor metastasis or invasion, periodontal disease and bone disease |
| 02/07/2002 | US20020016329 Inhibit p34cdc2/cyclin Bcdc13 kinase and protein tyrosine kinase pp60c-src and can be used for treatment of hyperproliferative diseases, for example chemotherapy of tumours or osteoporosis. |
| 02/07/2002 | US20020016328 Corticotropin releasing factor antagonists |
| 02/07/2002 | US20020016322 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use |
| 02/07/2002 | US20020016301 Preventing or treating emesis associated with a macrolide antibiotic comprising administering a Substance P antagonist, such as (2S,3S)-3-(5-tert-butyl-2-methoxybenzyl)amino-2-(3 -trifluromethoxylphenyl)piperidine |
| 02/07/2002 | US20020016299 Containing glycerolipid and/or glyceroglycolipid as effective component(s). |
| 02/07/2002 | US20020016293 Flavopiridol drug combinations and methods with reduced side effects |
| 02/07/2002 | US20020016285 Antitumor and/or antileukemic effects |
| 02/07/2002 | US20020015987 Peptide for use in the treatment of alzhiemer's, inflammation, cancer and immune defects |
| 02/07/2002 | US20020015984 Methods for ansamitocin production |
| 02/07/2002 | US20020015981 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 02/07/2002 | US20020015728 Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form |
| 02/07/2002 | US20020015704 Antibody, its binding portion or a probe is capable of binding to normal, benign, hyperplastic and cancerous epithelia cells and killing or ablating them; does not recognize antigens circulating in the blood |
| 02/07/2002 | US20020015703 Monoclonal antibodies or soluble immunoglobulin fusion proteins to block the development of chronic Graft-Versus-Host Disease |
| 02/07/2002 | US20020015679 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 02/07/2002 | DE10037310A1 Neue Indolderivate und deren Verwendung als Arzneimittel Novel indole derivatives and their use as medicaments |
| 02/07/2002 | DE10037146A1 Acetamidderivate Acetamide derivatives |
| 02/07/2002 | DE10036852A1 Urethanderivate Urethane |
| 02/07/2002 | DE10036121A1 N-Substituierte-1-amino-1,1-dialkyl-carbonsäurederivate N-substituted-1-amino-1,1-dialkyl-carboxylic acid derivatives |
| 02/07/2002 | DE10035854A1 Schlangentoxin und dessen Verwendung als Arzneimittel Snake toxin and its use as a medicament |
| 02/07/2002 | DE10035668A1 Diagnose und Therapie von HHV-8-assoziierten Erkrankungen auf der Grundlage des HHV-8-kodierten Chemokinrezeptors Diagnosis and treatment of HHV-8-associated disorders on the basis of HHV-8-encoded chemokine receptor |
| 02/07/2002 | DE10034607A1 Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren Multi-specific reagent for the selective stimulation of cell surface receptors |
| 02/07/2002 | CA2771263A1 Therapeutic polyesters and polyamides |
| 02/07/2002 | CA2426297A1 Agonist of follicle stimulating hormone activity |
| 02/07/2002 | CA2418115A1 Imidazole derivatives |
| 02/07/2002 | CA2417671A1 Trp8, trp9 and trp10, novel markers for cancer |
| 02/07/2002 | CA2417650A1 Indazole derivatives as jnk inhibitors and compositions and methods related thereto |
| 02/07/2002 | CA2417638A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor |
| 02/07/2002 | CA2417612A1 C3b/c4b complement receptor-like molecules and uses thereof |
| 02/07/2002 | CA2417574A1 Modified sialic acid vaccines |
| 02/07/2002 | CA2417550A1 Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
| 02/07/2002 | CA2417533A1 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent |
| 02/07/2002 | CA2417495A1 Methods for treating cell proliferative disorders and viral infections |
| 02/07/2002 | CA2417473A1 Use of polycyclic aromatic compounds for making medicines capable of inhibiting telomerase |
| 02/07/2002 | CA2417444A1 Nonsteroidal inflammation inhibitors |
| 02/07/2002 | CA2417359A1 Protein phosphatases |
| 02/07/2002 | CA2417349A1 Novel proteins and nucleic acids encoding same |
| 02/07/2002 | CA2417277A1 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta. |
| 02/07/2002 | CA2417262A1 Cdc25 phosphatase inhibitors |
| 02/07/2002 | CA2417259A1 Process for preparing arylacetylaminothiazoles |
| 02/07/2002 | CA2417254A1 N-¢5-¢¢¢5-alkyl-2-oxazolyl!methyl!thio!-2-thiazolyl! carboxamide inhibitors of cyclin dependent kinases |
| 02/07/2002 | CA2417204A1 Imidazolyl derivatives |
| 02/07/2002 | CA2417195A1 G-protein coupled receptors |
| 02/07/2002 | CA2417064A1 Cyclic polyamine compounds for cancer therapy |
| 02/07/2002 | CA2416978A1 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | CA2416893A1 Modified cea and uses thereof |
| 02/07/2002 | CA2416824A1 Use of an arylaldehyde 5-oxo-1, 2, 4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | CA2416820A1 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| 02/07/2002 | CA2416800A1 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 02/07/2002 | CA2416732A1 Endothelial cell expression patterns |
| 02/07/2002 | CA2416523A1 Dihydroporphyrin derivatives and their uses |
| 02/07/2002 | CA2416307A1 Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| 02/07/2002 | CA2416122A1 Vaginal delivery of bisphosphonates |
| 02/07/2002 | CA2415851A1 Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| 02/07/2002 | CA2415473A1 Apo-2l receptor agonist and cpt-11 synergism |
| 02/07/2002 | CA2415436A1 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| 02/07/2002 | CA2415433A1 A human disintegrin protein |
| 02/07/2002 | CA2415189A1 Immunomodulatory compounds |
| 02/07/2002 | CA2414623A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
| 02/07/2002 | CA2406311A1 Method for preventing and curing diseases of an immune system and a remedy for carrying out said method |